A detailed history of Capital Performance Advisors LLP transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 1 shares of GLSI stock, worth $14. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Holding current value
$14
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$12.99 - $17.58 $12 - $17
1 New
1 $0

Others Institutions Holding GLSI

About Greenwich LifeSciences, Inc.


  • Ticker GLSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,848,200
  • Market Cap $184M
  • Description
  • Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...
More about GLSI
Track This Portfolio

Track Capital Performance Advisors LLP Portfolio

Follow Capital Performance Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Performance Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Capital Performance Advisors LLP with notifications on news.